SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:uu-302225"
 

Search: onr:"swepub:oai:DiVA.org:uu-302225" > Outcomes of Allogen...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Chaudhury, SonaliAnn & Robert H Lurie Childrens Hosp Chicago, Dept Pediat Hematol Oncol & Stem Cell Transplanta, 225 E Chicago Ave, Chicago, IL 60611 USA. (author)

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia : A CIBMTR Cohort Analysis

  • Article/chapterEnglish2016

Publisher, publication year, extent ...

  • Elsevier BV,2016
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-302225
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-302225URI
  • https://doi.org/10.1016/j.bbmt.2016.02.015DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:133612249URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Chronic myeloid leukemia (CML) in children and young adults is uncommon. Young patients have long life expectancies and low morbidity with hematopoietic cell transplantation (HCT). Prolonged tyrosine kinase inhibitor (TKI) use may cause significant morbidity. In addition, indication for HCT in patients in the first chronic phase is not established. We hence retrospectively evaluated outcomes in 449 CML patients with early disease receiving myeloablative HCT reported to the CIBMTR. We analyzed various factors affecting outcome, specifically the effect of age and pre-HCT TKI in pediatric patients (age < 18 years, n = 177) and young adults (age 18 to 29 years, n = 272) with the goal of identifying prognostic factors. Post-HCT probability rates of 5-year overall survival (OS) and leukemia-free survival (LFS) were 75% and 59%, respectively. Rates of OS and LFS were 76% and 57% in <18-year and 74% and 60% in 18- to 29-year group, respectively, by univariate analysis (P = .1 and = .6). Five-year rates of OS for HLA matched sibling donor (MSD) and bone marrow (BM) stem cell source were 83% and 80%, respectively. In multivariate analysis there was no effect of age (<18 versus 18 to 29) or pre-HCT TKI therapy on OS, LFS, transplant related mortality, or relapse. Favorable factors for OS were MSD (P < .001) and recent HCT (2003 to 2010; P = .04). LFS was superior with MSD (P < .001), BM as graft source (P = .001), and performance scores > 90 (P = .03) compared with unrelated or mismatched peripheral blood stem cells donors and recipients with lower performance scores. Older age was associated with increased incidence of chronic graft-versus-host disease (P = .0002). In the current era, HCT outcomes are similar in young patients and children with early CML, and best outcomes are achieved with BM grafts and MSD.

Subject headings and genre

  • CML
  • Pediatrics

Added entries (persons, corporate bodies, meetings, titles ...)

  • Sparapani, RodneyMed Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. (author)
  • Hu, Zhen-HuanMed Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. (author)
  • Nishihori, TaigaUniv S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL 33612 USA. (author)
  • Abdel-Azim, HishamUniv So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Div Hematol Oncol & Blood & Marrow Transplantat, Los Angeles, CA 90033 USA. (author)
  • Malone, AdrianaIcahn Sch Med Mt Sinai, Bone Marrow & Stem Cell Transplantat, New York, NY 10029 USA. (author)
  • Olsson, RichardKarolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden(Swepub:uu)riols677 (author)
  • Hamadani, MehdiMed Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA.;Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Milwaukee, WI 53226 USA. (author)
  • Daly, AndrewUniv Calgary, Tom Baker Canc Ctr, Cumming Sch Med, Calgary, AB, Canada. (author)
  • Bacher, UlrikeUniv Canc Ctr Hamburg, Interdisciplinary Clin Stem Cell Transplantat, Hamburg, Germany. (author)
  • Wirk, Baldeep M.Seattle Canc Care Alliance, Div Bone Marrow Transplant, Seattle, WA USA. (author)
  • Kamble, Rammurti T.Baylor Coll Med, Ctr Cell & Gene Therapy, Div Hematol & Oncol, Houston, TX 77030 USA. (author)
  • Gale, Robert P.Univ London Imperial Coll Sci Technol & Med, Dept Med, Div Expt Med, Hematol Res Ctr, London, England. (author)
  • Wood, William A.Univ N Carolina, Div Hematol Oncol, Chapel Hill, NC USA. (author)
  • Hale, GregoryUniv S Florida, All Childrens Hosp, Dept Hematol Oncol, St Petersburg, FL 33701 USA. (author)
  • Wiernik, Peter H.Canc Res Fdn New York, Bronx, NY USA. (author)
  • Hashmi, Shahrukh K.Mayo Clin, Dept Blood & Marrow Transplantat, Rochester, MN USA. (author)
  • Marks, DavidUniv Hosp Bristol NHS Trust, Pediat Bone Marrow Transplant, Bristol, Avon, England. (author)
  • Ustun, CelalettinUniv Minneapolis, Div Hematol Oncol & Transplantat, Minneapolis, MN USA. (author)
  • Munker, ReinholdLouisiana State Univ Hlth Shreveport, Dept Internal Med, Sect Hematol Oncol, Shreveport, LA USA. (author)
  • Savani, Bipin N.Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA. (author)
  • Alyea, EdwinDana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA.;Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. (author)
  • Popat, UdayUniv Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA. (author)
  • Sobecks, RonaldCleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA. (author)
  • Kalaycio, MattCleveland Clin, Taussig Canc Inst, Dept Hematol & Med Oncol, Blood & Marrow Transplant Program, Cleveland, OH 44106 USA. (author)
  • Maziarz, RichardOregon Hlth & Sci Univ, Knight Canc Inst, Adult Blood & Marrow Stem Cell Transplant Program, Portland, OR 97201 USA. (author)
  • Hijiya, NobukoAnn & Robert H Lurie Childrens Hosp Chicago, Dept Pediat Hematol Oncol & Stem Cell Transplanta, 225 E Chicago Ave, Chicago, IL 60611 USA. (author)
  • Saber, WaelMed Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. (author)
  • Ann & Robert H Lurie Childrens Hosp Chicago, Dept Pediat Hematol Oncol & Stem Cell Transplanta, 225 E Chicago Ave, Chicago, IL 60611 USA.Med Coll Wisconsin, Dept Med, CIBMTR, Milwaukee, WI 53226 USA. (creator_code:org_t)

Related titles

  • In:Biology of blood and marrow transplantation: Elsevier BV22:6, s. 1056-10641083-87911523-6536

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view